EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib

Juliann Chmielecki, M. Catherine Pietanza, Dana Aftab, Ronglai Shen, Zhiguo Zhao, Xi Chen, Katherine Hutchinson, Agnes Viale, Mark G. Kris, Thomas Stout, Vincent Miller, Naiyer Rizvi, William Pao

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib'. Together they form a unique fingerprint.

Medicine & Life Sciences